deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01968213

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )

Sponsor: Foundation Medicine

Conditions Fallopian Tube Cancer Ovarian Cancer Peritoneal Cancer
Interventions Placebo Rucaparib
Updated 19 times since 2017 Last updated: Jun 7, 2023 Started: Apr 7, 2014 Primary completion: Apr 1, 2017 Completion: Jul 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Fallopian Tube Cancer and Ovarian Cancer and is currently completed. Foundation Medicine leads this study, which shows 19 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2022 · 13 months · monthly snapshot~Jul 2022 – ~Mar 2023 · 8 months · monthly snapshot~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jul 2023 — Oct 2023 [monthly]

    Completed PHASE3

▶ Show 14 earlier versions

  1. Mar 2023 — Jul 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jul 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Apr 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Dec 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Sep 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Jun 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  14. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Foundation Medicine
  • Myriad Genetics, Inc.
  • pharmaand GmbH
Data source: pharmaand GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Antwerp, Belgium , Asheville, United States , Auckland, New Zealand , Baltimore, United States , Barcelona, Spain , Bedford Park, Australia , Belfast, United Kingdom , Bologna, Italy , Bordeaux, France and 75 more locations